After the original deal fell through in August, Cook Medical sold products in its Maternal Fetal Medicine and gynecological surgery lines to CooperCompanies last month.
The sale closed for $300 million with the California-based company. The original deal made in 2022 was for $875 million, before CooperCompanies backed out.
That sale would have been for the entirety of Cook’s reproductive health business.
Read more: CooperCompanies cancels acquisition of Cook Medical reproductive health business
The deal last month does not include some fertility products from the original deal. It does include the Bakri Balloon, used to treat post-partum hemorrhaging, and Cook’s Doppler Blood Flow Monitor, which provides audio and visual feedback of a patient’s blood flow.
On quarterly calls from 2022 forward, CooperCompanies mentioned the deal was pending approval from the Federal Trade Commission.
Read more: Employees start moving into Spencer subdivision being built by Cook
Albert White, CooperCompanies’ President and CEO, said in March that it was exploring options to obtain approval.
“There’s a lot of regulatory implications here,” he said.
A statement from the Federal Trade Commission in August said the deal termination “ensures critical reproductive health markets remain competitive.”
The FTC statement called the cancellation a “win for patients.”
This comes after a 2021 executive order announcing stronger enforcement of anti-trust laws.
Read more: Cook Medical to cut 500 jobs under plan to refocus efforts
The product lines sold last month made up about 2.5 percent of Cook’s overall sales, according to the company.
No manufacturing jobs are at risk because of the sale, according to a Cook statement.
